Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Professional perspectives about pharmacogenetic testing and managing ancillary findings.

Haga SB, Tindall G, O'Daniel JM.

Genet Test Mol Biomarkers. 2012 Jan;16(1):21-4. doi: 10.1089/gtmb.2011.0045. Epub 2011 Jul 19.

2.

Ancillary risk information and pharmacogenetic tests: social and policy implications.

Henrikson NB, Burke W, Veenstra DL.

Pharmacogenomics J. 2008 Apr;8(2):85-9. Epub 2007 May 8. Review.

PMID:
17486108
3.

Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.

Haga SB, Mills R, Bosworth H.

Patient Educ Couns. 2014 Oct;97(1):10-5. doi: 10.1016/j.pec.2014.06.007. Epub 2014 Jun 21. Review.

4.

Attitudes of health care professionals toward pharmacogenetic testing.

Zgheib NK, Arawi T, Mahfouz RA, Sabra R.

Mol Diagn Ther. 2011 Apr 1;15(2):115-22. doi: 10.2165/11589490-000000000-00000. Review.

PMID:
21623646
5.

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.

Hess GP, Fonseca E, Scott R, Fagerness J.

Genet Res (Camb). 2015 Jun 1;97:e13. doi: 10.1017/S0016672315000099. Review.

PMID:
26030725
6.

Stakeholder views on pharmacogenomic testing.

Patel HN, Ursan ID, Zueger PM, Cavallari LH, Pickard AS.

Pharmacotherapy. 2014 Feb;34(2):151-65. doi: 10.1002/phar.1364. Epub 2013 Oct 24. Review.

PMID:
24167008
7.

Pharmacogenetics in psychiatry: translating research into clinical practice.

Malhotra AK, Zhang JP, Lencz T.

Mol Psychiatry. 2012 Jul;17(8):760-9. doi: 10.1038/mp.2011.146. Epub 2011 Nov 15. Review.

8.

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.

Roses AD.

Neuropsychopharmacology. 2009 Jan;34(1):6-17. doi: 10.1038/npp.2008.153. Epub 2008 Oct 15. Review.

9.

A review of consent practices and perspectives for pharmacogenetic testing.

Haga SB, Mills R.

Pharmacogenomics. 2016 Sep;17(14):1595-605. doi: 10.2217/pgs-2016-0039. Epub 2016 Aug 17. Review.

10.

Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.

Jansen ME, Rigter T, Rodenburg W, Fleur TMC, Houwink EJF, Weda M, Cornel MC.

Front Pharmacol. 2017 Aug 23;8:555. doi: 10.3389/fphar.2017.00555. eCollection 2017. Review.

Supplemental Content

Support Center